National Cancer Institute (NCI): Lymphoma trials
The registry lists 322 Lymphoma studies with National Cancer Institute (NCI) as lead sponsor. 13 are open to participants now and 126 have results posted.
Early Phase 1 2Phase 1 166Phase 2 161Phase 3 4No phase 25(a study in two phases counts in both)
Studies
Page 4 of 4. Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Penclomedine in Treating Patients With Solid Tumors or LymphomaCompletedNCT00002946Phase 1
- Phenylbutyrate in Treating Patients With Refractory Solid Tumors or LymphomaCompletedNCT00002909Phase 1
- Perillyl Alcohol in Treating Patients With Refractory CancerCompletedNCT00002862Phase 1
- Immunotoxin in Treating Patients With Leukemia or LymphomaCompletedNCT00002765Phase 1
- Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or LymphomaCompletedNCT00002759Phase 1
- Aminocamptothecin in Treating Patients With Refractory or Recurrent Hodgkin's Disease or Non-Hodgkin's LymphomaCompletedNCT00002745Phase 2
- Bryostatin-1 in Treating Patients With Recurrent Non-Hodgkin's LymphomaCompletedNCT00002725Phase 2
- Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's LymphomaCompletedNCT00002649Phase 3
- Topotecan and Radiation Therapy in Treating Patients With Solid Tumors or LymphomaCompletedNCT00002625Phase 1
- Combination Chemotherapy in Patients With Advanced or Recurrent Mycosis FungoidesStatus unknownNCT00002557Phase 2
- Evaluation, Treatment, and Natural History of Children and Young Adults With Cancer or Rare DiseasesCompletedNCT00001686
- Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and CancerCompletedNCT00001582
- Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin IdiotypeCompletedNCT00001572Phase 1
- EPOCH Chemotherapy +/- IL-12 for Previously Untreated and EPOCH Plus Rituximab for Previously Treated Patients With AIDS-Associated LymphomaCompletedNCT00001563Phase 2
- Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen VaccinesCompletedNCT00001512Phase 1
- A Randomized Study of EPOCH II Versus EPOCH II and Immunotherapy in LymphomasCompletedNCT00001430Phase 2
- Chronic and Late Effects of Non-Hodgkin's Lymphoma and Its Treatment in Long Term SurvivorsCompletedNCT00001301
- A Phase I Study of Continuous Infusion Immunotoxin IgG-RFB4-SMPT-dgA in Refractory CD22 Positive B-Cell LymphomaCompletedNCT00001271Phase 1
- Feasibility Study of Interleukin 1-Alpha With Ifosfamide, CBDCA, and Etoposide With Autologous Bone Marrow Transplant in Metastatic Carcinoma and LymphomaCompletedNCT00001270Phase 1
- Phase I Study of Intrathecal MafosfamideCompletedNCT00001251Phase 1
- Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) With Yttrium-90 Radiolabeled Anti-TacCompletedNCT00001249Phase 1
- Pilot Protocol for the Treatment of Patients With Small Non-Cleaved and Diffuse Large Cell LymphomasCompletedNCT00001237Phase 2